Euglycaemic diabetic ketoacidosis in patients using sodium‐glucose co‐transporter 2 inhibitors | Zendy

Isaacs Michelle | Zendy; Tonks Katherine T. | Zendy; Greenfield Jerry R. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Euglycaemic diabetic ketoacidosis in patients using sodium‐glucose co‐transporter 2 inhibitors

Author(s) -

Isaacs Michelle,

Tonks Katherine T.,

Greenfield Jerry R.

Publication year - 2017

Publication title -

internal medicine journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.596

H-Index - 70

eISSN - 1445-5994

pISSN - 1444-0903

DOI - 10.1111/imj.13442

Subject(s) - medicine , diabetic ketoacidosis , ketoacidosis , diabetes mellitus , complication , transporter , type 2 diabetes mellitus , type 2 diabetes , drug class , endocrinology , intensive care medicine , type 1 diabetes , pharmacology , drug , biochemistry , chemistry , gene

Sodium‐glucose co‐transporter 2 inhibitors ( SGLT2i ) are an increasingly prescribed class of medication for type 2 diabetes mellitus. Euglycaemic diabetic ketoacidosis ( euDKA ) has been reported in association with SGLT2i use. Clinicians need to understand how to recognise and treat this complication. We describe three cases of euDKA in patients treated with SGLT2i .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research